紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌疗效及安全性分析  

Efficacy and safety of paclitaxel liposomes combined with cisplatin in patients with advanced non-small-cell lung cancer

作　　者：邓明辉[1] 戴玉容[1] 

机构地区：[1]广东省惠州市惠阳区人民医院肿瘤内科,516211

出　　处：《临床合理用药杂志》2012年第14期12-14,共3页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的对比紫衫醇脂质体联合顺铂与普通紫衫醇联合顺铂治疗晚期非小细胞肺癌的疗效及安全性。方法将52例晚期非小细胞肺癌患者随机分为试验组和对照组各26例。试验组予以紫衫醇脂质体135mg/m2联合顺铂治疗,对照组予以普通紫衫醇135mg/m2联合顺铂治疗。2组均以21d为1个周期,治疗4个周期后第4周评价疗效及安全性。结果试验组2例、对照组5例未完成化疗周期。2组临床疗效及血液学毒性反应发生情况比较差异无统计学意义(P>0.05)。试验组皮疹、呼吸困难、肌肉/关节酸痛发生率均低于对照组,差异均有统计学意义(P<0.05)。试验组周围神经病变发生率较对照组低,但差异无统计学意义(P>0.05)。2组恶心/呕吐、腹泻、腹痛、脱发、等发生率比较差异均无统计学意义(P>0.05)。结论紫衫醇脂质体联合顺铂治疗晚期非小细胞肺癌疗效与紫杉醇相当,但过敏反应明显降低。Objective To compare the efficacy and safety of Paclitaxel liposomes with Paclitaxel in Patients with advanced non-small-cell lung cancer（NSCLC）.Methods 52 patients with advanced non-small-cell lung cancer were randomly allocated to receive either 135mg/m2 of Paclitaxel liposome and cisplatin（experiment group） or 135mg/m2 paclitaxel and cisplatin（control group）.Considered every 3 weeks as a cycle.The efficacy and safety were evaluated four weeks after four cycles.Results There was no significant differences in efficacy and non-hematological toxicity betweent the two groups（P0.05）.The hypersensitivity such as rash,respiratory distress,muscles or extremities pain were significant lower in experimental group than those in control group（P0.05）.Peripheral neuropathy was lower in experimental group,but made no significant differences（P0.05）.Conclusion Paclitaxel liposome combined with cisplatin in the treatment of advanced NSCLC can reduce the incidence of hypersensitivity reactions with the similar response rate as that of Paclitaxel.

关 键 词：紫杉醇脂质体 紫杉醇 非小细胞肺癌 疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]